Literature DB >> 17483247

A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

P Riley1, J O'Donohue, M Crook.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder in western countries, and its incidence is increasing. This review outlines the significant health burden posed by NAFLD and discusses what is presently known about its pathogenesis, including the roles of the metabolic syndrome, obesity, insulin resistance, hepatic steatosis, reactive oxygen species, inflammatory cytokines and adipocytokines. The way in which NAFLD is clinically diagnosed is described, and areas of uncertainty surrounding its investigation are identified, before discussing the relative merits of the limited treatment options available and looking ahead to potential therapeutic strategies for the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483247      PMCID: PMC2095560          DOI: 10.1136/jcp.2006.044891

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  146 in total

Review 1.  Hepatitis C: a metabolic liver disease.

Authors:  Steven A Weinman; L Maria Belalcazar
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

Review 2.  Nonalcoholic fatty liver disease: a clinical review.

Authors:  David A Sass; Parke Chang; Kapil B Chopra
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

3.  Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease.

Authors:  Zhiping Li; Mark J Soloski; Anna Mae Diehl
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

4.  Metformin reverses fatty liver disease in obese, leptin-deficient mice.

Authors:  H Z Lin; S Q Yang; C Chuckaree; F Kuhajda; G Ronnet; A M Diehl
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

5.  Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.

Authors:  Kevin B Barker; Nicole A Palekar; Steven P Bowers; Joel E Goldberg; Joseph P Pulcini; Stephen A Harrison
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

Review 6.  Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.

Authors:  Andreas Schäffler; Jürgen Schölmerich; Christa Büchler
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-06

7.  Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.

Authors:  Laetitia Fartoux; Olivier Chazouillères; Dominique Wendum; Raoul Poupon; Lawrence Serfaty
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

8.  Liver dysfunction following small-bowel bypass for obesity. Nonoperative treatment of fatty metamorphosis with parenteral hyperalimentation.

Authors:  F C Ames; E M Copeland; D C Leeb; D L Moore; S J Dudrick
Journal:  JAMA       Date:  1976-03-22       Impact factor: 56.272

9.  Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.

Authors:  Sean W P Koppe; Atul Sahai; Padmini Malladi; Peter F Whitington; Richard M Green
Journal:  J Hepatol       Date:  2004-10       Impact factor: 25.083

Review 10.  Prevention and treatment of the metabolic syndrome.

Authors:  S S Daskalopoulou; D P Mikhailidis; M Elisaf
Journal:  Angiology       Date:  2004 Nov-Dec       Impact factor: 3.619

View more
  7 in total

1.  Current and novel therapies for the treatment of nonalcoholic steatohepatitis.

Authors:  David van der Poorten; Jacob George
Journal:  Hepatol Int       Date:  2007-07-26       Impact factor: 6.047

2.  Laparoscopic Adjustable Gastric Banding In Patients with Unexpected Cirrhosis: Safety and Outcomes.

Authors:  Richard M Woodford; Paul R Burton; Paul E O'Brien; Cheryl Laurie; Wendy A Brown
Journal:  Obes Surg       Date:  2015-10       Impact factor: 4.129

Review 3.  Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK.

Authors:  Joachim H Ix; Kumar Sharma
Journal:  J Am Soc Nephrol       Date:  2010-02-11       Impact factor: 10.121

4.  Alterations in liver sinusoidal endothelium in a baboon model of type 1 diabetes.

Authors:  H A Jamieson; V C Cogger; S M Twigg; S V McLennan; A Warren; R Cheluvappa; S N Hilmer; R Fraser; R de Cabo; D G Le Couteur
Journal:  Diabetologia       Date:  2007-06-29       Impact factor: 10.122

Review 5.  Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.

Authors:  Rosa Lombardi; Simona Onali; Douglas Thorburn; Brian R Davidson; Kurinchi Selvan Gurusamy; Emmanuel Tsochatzis
Journal:  Cochrane Database Syst Rev       Date:  2017-03-30

6.  Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.

Authors:  Elena Buzzetti; Audrey Linden; Lawrence Mj Best; Angela M Madden; Danielle Roberts; Thomas J G Chase; Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Dominic Fritche; Elisabeth Jane Milne; Kathy Wright; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-06-11

7.  Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.

Authors:  Oluyemi Komolafe; Elena Buzzetti; Audrey Linden; Lawrence Mj Best; Angela M Madden; Danielle Roberts; Thomas Jg Chase; Dominic Fritche; Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Elisabeth Jane Milne; Kathy Wright; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-07-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.